» Articles » PMID: 38348246

The Many Faces of COPD in Real Life: a Longitudinal Analysis of the NOVELTY Cohort

Overview
Journal ERJ Open Res
Specialty Pulmonary Medicine
Date 2024 Feb 13
PMID 38348246
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The diagnosis of COPD requires the demonstration of non-fully reversible airflow limitation by spirometry in the appropriate clinical context. Yet, there are patients with symptoms and relevant exposures suggestive of COPD with either normal spirometry (pre-COPD) or preserved ratio but impaired spirometry (PRISm). Their prevalence, clinical characteristics and associated outcomes in a real-life setting are unclear.

Methods: To investigate them, we studied 3183 patients diagnosed with COPD by their attending physician included in the NOVELTY study (clinicaltrials.gov identifier NCT02760329), a global, 3-year, observational, real-life cohort that included patients recruited from both primary and specialist care clinics in 18 countries.

Results: We found that 1) approximately a quarter of patients diagnosed with (and treated for) COPD in real life did not fulfil the spirometric diagnostic criteria recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), and could be instead categorised as pre-COPD (13%) or PRISm (14%); 2) disease burden (symptoms and exacerbations) was highest in GOLD 3-4 patients (exacerbations per person-year (PPY) 0.82) and lower but similar in those in GOLD 1-2, pre-COPD and PRISm (exacerbations range 0.27-0.43 PPY); 3) lung function decline was highest in pre-COPD and GOLD 1-2, and much less pronounced in PRISm and GOLD 3-4; 4) PRISm and pre-COPD were not stable diagnostic categories and change substantially over time; and 5) all-cause mortality was highest in GOLD 3-4, lowest in pre-COPD, and intermediate and similar in GOLD 1-2 and PRISm.

Conclusions: Patients diagnosed COPD in a real-life clinical setting present great diversity in symptom burden, progression and survival, warranting medical attention.

Citing Articles

Differences in Blood Eosinophil Level During Stable Disease and During Exacerbation of COPD and Exacerbation Risks.

Kwok W, Tam T, Chau C, Lam F, Man Ho J Lung. 2025; 203(1):37.

PMID: 40016611 PMC: 11868221. DOI: 10.1007/s00408-025-00792-9.


Of Mucus and Microbes: The Sticky Issue of Mucin-Microbiome Interactions in Chronic Obstructive Pulmonary Disease.

Huang Y Am J Respir Crit Care Med. 2024; 210(3):252-253.

PMID: 38530107 PMC: 11348977. DOI: 10.1164/rccm.202403-0506ED.

References
1.
McKleroy W, Shing T, Anderson W, Arjomandi M, Awan H, Barjaktarevic I . Longitudinal Follow-Up of Participants With Tobacco Exposure and Preserved Spirometry. JAMA. 2023; 330(5):442-453. PMC: 10394572. DOI: 10.1001/jama.2023.11676. View

2.
Marott J, Ingebrigtsen T, Colak Y, Vestbo J, Lange P . Trajectory of Preserved Ratio Impaired Spirometry: Natural History and Long-Term Prognosis. Am J Respir Crit Care Med. 2021; 204(8):910-920. DOI: 10.1164/rccm.202102-0517OC. View

3.
Kim J, Lee C, Lee H, Kim H . Association between Comorbidities and Preserved Ratio Impaired Spirometry: Using the Korean National Health and Nutrition Examination Survey IV-VI. Respiration. 2021; 101(1):25-33. PMC: 8820418. DOI: 10.1159/000517599. View

4.
Wan E, Castaldi P, Cho M, Hokanson J, Regan E, Make B . Epidemiology, genetics, and subtyping of preserved ratio impaired spirometry (PRISm) in COPDGene. Respir Res. 2014; 15:89. PMC: 4256936. DOI: 10.1186/s12931-014-0089-y. View

5.
Colak Y, Nordestgaard B, Vestbo J, Lange P, Afzal S . Relationship between supernormal lung function and long-term risk of hospitalisations and mortality: a population-based cohort study. Eur Respir J. 2020; 57(4). DOI: 10.1183/13993003.04055-2020. View